Aspergillus in the intensive care unit

被引：1
作者：
Markus Ruhnke
Peter Kujath
Dirk Vogelaers
机构：
[1] Medizinische Klinik und Poliklinik, M. S. Onkologie and Hämatologie, Charité Universitätsmedizin Berlin, Campus Charité Mitte, 10117 Berlin
[2] Klinik für Chirurgie, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lübeck
[3] Department of Infectious Diseases, Ghent University Hospital, Ghent
来源：
Current Fungal Infection Reports | 2012年 / 6卷 / 1期
关键词：
Antifungal therapy; Aspergillosis; Aspergillus; Diagnosis; Epidemiology; Fungal infection; ICU; Intensive care unit; Invasive fungal disease; Prognosis; Prophylaxis; Risk factors; Treatment;
D O I：
10.1007/s12281-011-0078-2
中图分类号：
学科分类号：
摘要：
Invasive aspergillosis (IA), the most life-threatening form of aspergillosis, has become a major opportunistic fungal disease in immunocompromised patients. In high-risk patients with hematologic malignancies, IA appears to decline with the use of mold-active antifungal prophylaxis, but the situation is less clear in other patient groups at risk for IA, and precise epidemiologic data from patients treated in intensive care units (ICUs) are lacking. Most Aspergillus culture isolates from nonsterile body sites do not represent disease, but isolation of Aspergillus in critically ill patients is a marker of poor prognosis and is associated with high mortality regardless of invasion or colonization. This review presents current information on epidemiology, risk factors, and diagnosis, and discusses treatment options for patients with IA in the ICU. © 2012 Springer Science+Business Media, LLC.
引用
收藏
页码：63 / 73
页数：10
相关论文
共 67 条
[1]  
Hope W.W., Walsh T.J., Denning D.W., The invasive and saprophytic syndromes due to Aspergillus spp, Medical Mycology, 43, SUPPL.1, (2005)
[2]  
Depauw B., Walsh T.J., Donnelly J.P., Stevens D.A., Edwards J.E., Calandra T., Et al., Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group, Clin Infect Dis., 46, 12, pp. 1813-1821, (2008)
[3]  
Patterson T.F., Kirkpatrick W.R., White M., Hiemenz J.W., Wingard J.R., Dupont B., Et al., Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group, Medicine (Baltimore)., 79, 4, pp. 250-260, (2000)
[4]  
Ascioglu S., Rex J.H., De Pauw B., Bennett J.E., Bille J., Crokaert F., Denning D.W., Donnelly J.P., Edwards J.E., Erjavec Z., Fiere D., Lortholary O., Maertens J., Meis J.F., Patterson T.F., Ritter J., Selleslag D., Shah P.M., Stevens D.A., Walsh T.J., Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus, Clinical Infectious Diseases, 34, 1, pp. 7-14, (2002)
[5]  
Jensen J., Guinea J., Torres-Narbona M., Munoz P., Pelaez T., Bouza E., Post-surgical invasive aspergillosis: An uncommon and underappreciated entity, J Infect., 60, 2, pp. 162-167, (2010)
[6]  
Neofytos D., Horn D., Anaissie E., Steinbach W., Olyaei A., Fishman J., Et al., Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: Analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry, Clin Infect Dis., 48, 3, pp. 265-273, (2009)
[7]  
Cornely O.A., Maertens J., Winston D.J., Perfect J., Ullmann A.J., Walsh T.J., Helfgott D., Holowiecki J., Stockelberg D., Goh Y.-T., Petrini M., Hardalo C., Suresh R., Angulo-Gonzalez D., Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia, New England Journal of Medicine, 356, 4, pp. 348-359, (2007)
[8]  
Chamilos G., Luna M., Lewis R.E., Bodey G.P., Chemaly R., Tarrand J.J., Safdar A., Raad I.I., Kontoyiannis D.P., Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: An autopsy study over a 15-year period (1989-2003), Haematologica, 91, 7, pp. 986-989, (2006)
[9]  
Donhuijsen K., Petersen P., Schmid K., Trend Reversal in the frequency of mycoses in hematological neoplasias, Dtsch Arztebl., 105, 28-29, pp. 501-506, (2008)
[10]  
Lehrnbecher T., Frank C., Engels K., Kriener S., Groll A.H., Schwabe D., Trends in the postmortem epidemiology of invasive fungal infections at a university hospital, J Infect., 61, 3, pp. 259-265, (2010)
1234567